New molecular insights in tobacco-induced lung cancer

Future Oncology

Volumn 9, Issue 5, 2013, Pages 649-655

  Tonini, Giuseppe ^a   D'Onofrio, Loretta ^a   Dell'Aquila, Emanuela ^a   Pezzuto, Aldo ^b  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

7nAChR; cigarette smoking; COX2 pathway; lung cancer; nicotine; PPAR

Indexed keywords

BETA TUBULIN; CASPASE 3; CYCLOOXYGENASE 2; F ACTIN; FIBROBLAST GROWTH FACTOR 2; GELATINASE B; INTERLEUKIN 8; NICOTINE; NICOTINIC RECEPTOR; NITROSAMINE; POLYCYCLIC AROMATIC HYDROCARBON; PROTEIN BCL 2; VASCULOTROPIN A;

ANGIOGENESIS; ARTICLE; CANCER GROWTH; CELL MIGRATION; CELL PROLIFERATION; DNA ADDUCT; EXTRACELLULAR MATRIX; GENETIC ASSOCIATION; HUMAN; LONG TERM EXPOSURE; LUNG CANCER; LUNG CARCINOGENESIS; LUNG NODULE; LUNG NON SMALL CELL CANCER; LYMPHANGIOGENESIS; METABOLIC ACTIVATION; NATURAL KILLER CELL; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; TOBACCO DEPENDENCE; TUMOR PROMOTION;

CARCINOGENS; HUMANS; LUNG NEOPLASMS; SMOKING;

EID: 84877629896     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.13.32     Document Type: Article

References (72)

1. WHO; International Agency for Research on Cancer. IARC Monographs on the Evaluation of the Carcinogetic Risks of Chemicals to Humans, Volume 83: Tobacco Smoking and Tobacco Smoke. International Agency for Research on Cancer, Lyon, France (2004).
2. Petros WP, Younis IR, Ford JN, et al. Effects of tobacco smoking and nicotine on cancer treatment. Pharmacotherapy 32, 920-931 (2012).
3. Wen J, Fu JH, Zhang W, et al. Lung carcinoma signaling pathways activated by smoking. Chin. J. Cancer 30, 551-558 (2011).
4. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N. Engl. J. Med. 359, 1367-1380 (2008).
5. Hecht SS. Cigarette smoking and cancer. In: Environmental and Occupational Medicine. Rom WN (Ed.). Lippincott-Raven, NY, USA, 1479-1499 (1998).
6. Hecht SS, Murphy SE, Carmella SG, et al. Tobacco carcinogens, their biomarkers and tobacco-induced cancer. Nat. Rev. Cancer 3, 733-744 (2003).
7. Amin S, Desai D, Hecht SS, et al. Synthesis of tobacco-specific N-nitrosamines and their metabolites and results of related bioassays. Crit. Rev. Toxicol. 26, 139-147 (1996).
8. Nesnow S, Ross JA, Stoner GD, et al. Mechanistic linkage between DNA adducts, mutations in oncogenes and tumorigenesis of carcinogenic environmental polycyclic aromatic hydrocarbons in strain A/J mice. Toxicology 105, 403-413 (1995).
9. Hecht SS. Biochemistry, biology, and carcinogenicity of tobacco-specific N-nitrosamines. Chem. Res. Toxicol. 11, 559-603 (1998).
10. Li W, Yue W, Zhang L, Zhao X, et al. Polymorphisms in GSTM1, CYP1A1, CYP2E1, and CYP2D6 are associated with susceptibility and chemotherapy response in non-small-cell lung cancer patients. Lung 190, 91-98 (2012).
11. Anttila S, Raunio H, Hakkola J. Cytochrome P450-mediated pulmonary metabolism of carcinogens: regulation and cross-talk in lung carcinogenesis. Am. J. Respir. Cell Mol. Biol. 44, 583-590 (2011).
12. Peterson LA. Formation, repair, and genotoxic properties of bulky DNA adducts formed from tobacco-specific nitrosamines. J. Nucleic Acids 5, 2010 (2010).
13. Waldum HL, Nilsen OG, Nilsen T, et al. Long-term effects of inhaled nicotine. Life Sci. 58, 1339-1346 (1996).
14. Song P, Sekhon HS, Jia Y, et al. Acetylcholine is synthesized by and acts as an autocrine growth factor for small cell lung carcinoma. Cancer Res. 63, 214-221 (2003).
15. Schuller HM. Cell type specific receptor-mediated modulation of growth kinetics in human lung cancer cell lines by nicotine and tobacco-related nitrosamines. Biochem. Pharmacol. 38, 3439-3442 (1989).
16. Improgo MR, Scofield MD, Tapper AR, et al. The nicotinic acetylcholine receptor CHRNA5/A3/B4 gene cluster: dual role in nicotine addiction and lung cancer. Prog. Neurobiol. 92, 212-226 (2010).
17. Improgo MR, Scofield MD, Tapper AR, et al. From smoking to lung cancer: the CHRNA5/A3/B4 connection. Oncogene 29, 4874-4884 (2010).
18. Puliyappadamba VT, Cheriyan VT, Thulasidasan AK, et al. Nicotine-induced survival signaling in lung cancer cells is dependent on their p53 status while its down-regulation by curcumin is independent. Mol. Cancer 9, 220 (2010).
19. Schuller HM. Is cancer triggered by altered signalling of nicotinic acetylcholine receptors? Nat. Rev. Cancer 9, 195-205 (2009).
20. Schuller HM. Regulatory role of the a7nAChR in cancer. Curr. Drug Targets 13, 680-687 (2012).
21. Catassi A, Servent D, Paleari L, et al. Multiple roles of nicotine on cell proliferation and inhibition of apoptosis: implications on lung carcinogenesis. Mutation Res. 659, 221-231 (2008).
22. Zhang J, Kamdar O, Wei L. Nicotine induces resistance to chemotherapy by modulating mithocondrial signaling in lung cancer. Am. J. Respir. Cell. Mol. Biol. 40, 135-146 (2009).
23. Jull B, Plummer H, Schuller H. Nicotinic receptor mediated activation by the tobacco-specific nitrosamine NNK of a Raf-1/MAP kinase pathway, resulting in phosphorylation of c-myc in human small cell lung carcinoma cellsv and pulmonary neuroendocrine cells. J. Cancer Res. Clin. Oncol. 127, 707-717 (2001).
24. Zheng Y, Ritzenthaler JD, Roman J, et al. Nicotine stimulates human lung cancer cell growth by inducing fibronectin expression. Am. J. Respir. Cell Mol. Biol. 37, 681-690 (2007).
25. Alama A, Bruzzo C, Cavalieri Z, et al. Inhibition of the nicotinic acetylcholine receptors by cobra venom a-neurotoxins: is there a perspective in lung cancer treatment? PLoS One 6, e20695 (2001).
26. Cesario A, Russo P, Nastrucci C, et al. Is a7-nAChR a possible target for lung cancer and malignant pleural mesothelioma treatment? Curr. Drug Targets 13, 688-694 (2012).
27. Brown KC, Lau JK, Dom AM, et al. MG624, an a7-nAChR antagonist, inhibits angiogenesis via the Egr-1/FGF2 pathway. Angiogenesis 15, 99-114 (2012).
28. Wong HPS, Yu LE, Lam EKY, et al. Nicotine promotes colon tumor growth and angiogenesis through b-adrenergic activation. Toxicol. Sci. 97, 279-287 (2007).
29. Schuller HM, Cekanova M. NNK induced hamster lung adenocarcinomas overexpress beta2 adrenergic and EGFR signalling pathways. Lung cancer 49, 35-45 (2005).
30. Schuller HM, Tithof PK, Williams M, et al. The tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1 butanone is a beta-adrenergic agonist and stimulates DNA synthesis in lung adenocarcinoma via beta-adrenergic receptor-mediated release of arachidonic acid. Cancer Res. 59, 4510-4515 (1999).
31. Wong HP, Yu L, Lam EK, et al. Nicotine promotes cell proliferation via alpha7-nicotinic acetylcholine receptor and catecholamine-synthesizing enzymes-mediated pathway in human colon adenocarcinoma HT-29 cells. Toxicol. Appl. Pharmacol. 221, 261-267 (2007).
32. Palm D, Lang K, Niggemann B, et al. The norepinephrine-driven metastasis development of PC-3 human prostate cancer cells in BALB/c nude mice is inhibited by beta-blockers. Int. J. Cancer 118, 2744-2749 (2006).
33. Sood AK, Bhatty R, Kamat AA, et al. Stress hormone-mediated invasion of ovarian cancer cells. Clin. Cancer Res. 12, 369-375 (2006).
34. Al-Wadei HA, Plummer HK 3rd, Schuller HM. Nicotine stimulates pancreatic cancer xenografts by systemic increase in stress neurotransmitters and suppression of the inhibitory neurotransmitter gamma-aminobutyric acid. Carcinogenesis 30, 506-511 (2009).
35. Al-Wadei HA, Al-Wadei MH, Schuller HM. Cooperative regulation of non-small cell lung carcinoma by nicotinic and beta-adrenergic receptors: a novel target for intervention. PLoS One 7, e29915 (2012).
36. Huang RY, Chen GG. Cigarette smoking, cyclooxygenase-2 pathway and cancer. Biochim. Biophys. Acta 1815(2), 158-169 (2011).
37. Strillacci A, Grifoni C, Valerii MC, et al. RNAi-based strategies for cyclooxygenase-2 inhibition in cancer. J. Biomed. Biotechnol. 2010, 8280458 (2010).
38. Krzystyniak KL. Current strategies for anticancer chemoprevention and chemoprotection. Acta Pol. Pharm. 59, 473-478 (2002).
39. Saha D, Pyo H, Choy H. COX-2 inhibitor as a radiation enhancer: new strategies for the treatment of lung cancer. Am. J. Clin. Oncol. 26, S70-S74 (2003).
40. Bhoopathi P, Chetty C, Gujrati M, et al. The role of MMP-9 in the anti-angiogenic effect of secreted protein acidic and rich in cysteine. Br. J. Cancer 102, 530-540 (2010).
41. Schuller HM, Porter B, Riechert A. Beta-adrenergic modulation of NNK-induced lung carcinogenesis in hamsters. J. Cancer Res. Clin. Oncol. 126, 624-630 (2000).
42. Nie D, Lamberti M, Zacharek A, et al. Thromboxane A(2) regulation of endothelial cell migration, angiogenesis, and tumor metastasis. Biochem. Biophys. Res. Commun. 267, 245-251 (2000).
43. Heeschen C, Jang JJ, Weis M, et al. Nicotine stimulates angiogenesis and promotes tumor growth and atherosclerosis. Nat. Med. 7, 833-839 (2001).
44. Conklin BS, Zhao W, Zhong DS, et al. Nicotine and cotinine up-regulate vascular endothelial growth factor expression in endothelial cells. Am. J. Pathol. 160, 413-418 (2002).
45. Heeschen C, Weis M, Aicher A, et al. A novel angiogenic pathway mediated by nonneuronal nicotinic acetylcholine receptors. J. Clin. Invest. 110, 527-536 (2002).
46. Ng MKC, Wu J, Chang E, et al. A central role for nicotinic cholinergic regulation of growth factor-induced endothelial cell migration. Arteriosclerosis Thrombosis Vasc. Biol. 1, 106-112 (2007).
47. Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease: an update. J. Am. Coll. Cardiol. 43, 1731-1737 (2004).
48. Arias HR, Richards VE, Ng D, et al. Role of non-neuronal nicotinic acetylcholine receptors in angiogenesis. Int. J. Biochem. Cell Biol. 41, 1441-1451 (2009).
49. Wiesner T, Bugle S, Mayer F, et al. Differential changes in platelet VEGF, Tsp, CXCL12, CXCL4 in patients with metastatic cancer. Clin. Exp. Metastasis 27, 141-149 (2010).
50. Hung FL, Young R, Hect S. Formation of cyclic N-propanodeoxyguanosine adducts in DNA upon reaction with acrolein or crotonaldehyde. Cancer Res. 44, 990-995 (1984).
51. Feng Z, Hu W, Hu Y, et al. Acrolein is a major cigarette-related lung cancer agent. Preferential binding at p53 mutational hotspots and inhibition of DNA repair. Proc. Natl Acad. Sci. USA 103, 15404-15409 (2006).
52. Profita M, Bonanno A, Montalbano AM, et al. Cigarette smoke extract activates human bronchial epithelial cells affecting non neural cholinergic system signalling in vitro. Life Sci. 89, 36-43 (2011).
53. Horvathova M, Jhanova E, Szabova M, et al. The relationship between cell surface markers, cytokines, ageing and cigarette smoking. Bratisl. Lek. Listy 110, 394-400 (2009).
54. Therriault MJ, Proulx LI, Castonguay A, et al. Immunomodulatory effects of the tobacco-specific carcinogen, NNK, on alveolar macrophages. Clin. Exp. Immunol. 132, 232-238 (2003).
55. Zeidel A, Beilin B, Yardeni I, et al. Immune response in asymptomatic smokers. Acta Anaesthesiol. Scand. 46(8), 959-964 (2002).
56. Bhalla D, Hirata F, Rishi A, et al. Cigarette smoke, inflammation and lung injury: a mechanistic perspective. J. Toxicol. Environ. Health 12, 45-64 (2009).
57. Pillai S, Chellappan S. a7 nicotinic acetylcholine receptor subunit in angiogenesis and epithelial to mesenchymal transition. Curr. Drug Targets 13, 671-679 (2012).
58. Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and disease. Nature 405, 421 (2000).
59. Yuan H, Li MY, Ma LT, et al. 15-lipoxygenases and its metabolites 15(S)-HETE and 13(S)-HODE in the development of non-small cell lung cancer. Thorax 65, 321-326 (2010).
60. Li MY, Yuan H, Ma LT, et al. Roles of peroxisome proliferator-activated receptor-alpha and-gamma in the development of non-small cell lung cancer. Am. J. Respir. Cell Mol. Biol. 43, 674-683 (2010).
61. Li MY, Kong AW, Yuan H, et al. Pioglitazone prevents smoking carcinogen-induced lung tumor development in mice. Curr. Cancer Drug Targets 12, 597-606 (2012).
62. Satoh T, Toyoda M, Hoshino H, et al. Activation of peroxisome proliferator-activated receptor-gamma stimulates the growth arrest and DNA-damage inducible 153 gene in non-small cell lung carcinoma cells. Oncogene 21, 2171-2180 (2002).
63. Mao JT, Nie WX, Tsu IH, et al. White tea extract induces apoptosis in non-small cell lung cancer cells: the role of peroxisome proliferator-activated receptor-{gamma} and 15-lipoxygenases. Cancer Prev. Res. (Phila.) 3, 1132-1140 (2010).
64. Murin S, K. Pinkerton E, Hubbard NE, et al. The effect of cigarette smoke exposure on pulmonary metastatic disease in a murine model of metastatic breast cancer. Chest 125, 1467-1471 (2004).
65. Dasgupta P, Rizwani W, Pillai S, et al. Nicotine induces cell proliferation, invasion and epithelial-mesenchymal transition in a variety of human cancer cell lines. Int. J. Cancer 124, 36-45 (2009).
66. Yoshino I, Kometani T, Shoji F, et al. Induction of epithelial- mesenchymal transition-related genes by benzo[a]pyrene in lung cancer cells. Cancer 110, 369-374 (2007).
67. Martinez-Garcia E, Irigoyen M, Gonzalez-Moreno O, et al. Repetitive nicotine exposure leads to a more malignant and metastasis-prone phenotype of SCLC: a molecular insight into the importance of quitting smoking during treatment. Toxicol. Sci. 116, 467-476 (2010).
68. Truong T, Hung RJ, Amos CI, et al. Replication of lung cancer susceptibility loci at chromosomes 15q25, 5p15, and 6p21: a pooled analysis from the International Lung Cancer Consortium. J. Natl Cancer Inst. 102, 959-971 (2010).
69. Amos C, Wu X, Broderick P, et al. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat. Genet. 40, 616-622 (2008).
70. Saccone SF, Hinrichs AL, Saccone NL, et al. Cholinergic nicotinic receptor genes implicated in a nicotine dependence association study targeting 348 candidate genes with 3713 SNPs. Hum. Mol. Genet. 16, 36-49 (2007).
71. Galvan A, Dragani TA. Nicotine dependence may link the 15q25 locus to lung cancer risk. Carcinogenesis 31, 331-333(2010).
72. Harari O, Wang JC, Bucholz K, et al. Pathway analysis of smoking quantity in multiple GWAS identifies cholinergic and sensory pathways. PLoS One 7, e50913 (2012).